From 2026, vaccine reimbursement in Czechia will follow a more predictable and systematic process, removing the need for legislative amendments each time a new vaccine is introduced. This reform is expected to improve access to modern vaccines. Under the amended Act on Public Health Insurance, the State Institute for Drug Control (SÚKL) will determine the level and conditions of reimbursement for immunization-related medicinal products through a formal health technology assessment (HTA) process. HTA will consider medical, social, economic and ethical aspects, along with the broader public health impact of each vaccine.
To support better access and uptake of vaccines, the Ministry of Health also submitted a draft of the country’s first comprehensive National Vaccination Strategy for internal consultation in July 2025. The strategy addresses the full vaccination life cycle – from vaccine approval and reimbursement to communication with the public and healthcare professionals and evaluation of the immunization programme. Aiming to improve coordination, transparency and public trust in vaccination, the strategy is expected to be approved by the government by the end of 2025.